Merck, SpringWorks
We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...
This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck reported adjusted EPS of $1.72 ... up from a prior $129. Across the commercial portfolio, the analyst remains bullish on Winrevair's potential. Analyst Shibutani writes that the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback